LAS VEGAS, July 13, 2010 (GLOBE NEWSWIRE) -- Skinvisible, Inc. (OTCBB:SKVI) and RHEI Pharmaceuticals, a Hong Kong-based pharmaceutical company and a subsidiary of the Luxembourg-based Leeward Ventures SICAR SCA, announce the completion of an exclusive license agreement granting RHEI, the exclusive rights to three Skinvisible formulations developed using its patented Invisicare polymer delivery system.
